Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa.

The Journal of antimicrobial chemotherapy - 30 Sept 2022

Gill Christian M, Oliver Antonio, Fraile-Ribot Pablo Arturo, Nicolau David P

Abstract excerpt

OBJECTIVES: To evaluate the in vivo killing profile of human-simulated exposures of ceftazidime, ceftazidime/avibactam and meropenem against GES-harbouring Pseudomonas aeruginosa in the murine thigh infection model. METHODS: Five P. aeruginosa isolates [three isogenic (GES-1, GES-5 and GES-15) and two clinical (GES-5 and GES-15)] were evaluated. MICs were determined using broth microdilution. Human-simulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Azabicyclo Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ceftazidime

Share to Drug Combinations

Share to Meropenem

Share to Microbial Sensitivity Tests

Share to Pseudomonas aeruginosa

Source

Open in PubMed Open full text

Identifiers

PMID: 35848936
DOI: 10.1093/jac/dkac232
PMCID: PMC9525071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa.PMID 35848936Read ↗

Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.Semantic proximity Read ↗

Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosaSemantic proximity Read ↗

In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae IsolatesSemantic proximity Read ↗

GES-18, a New Carbapenem-Hydrolyzing GES-Type β-Lactamase from Pseudomonas aeruginosa That Contains Ile80 and Ser170 ResiduesSemantic proximity Read ↗

Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications.Semantic proximity Read ↗

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelSemantic proximity Read ↗

Extremely Drug-Resistant <i>Pseudomonas aeruginosa</i> ST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United StatesSemantic proximity Read ↗

In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteriaSemantic proximity Read ↗

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Semantic proximity Read ↗

Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro EvidenceSemantic proximity Read ↗

Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.Semantic proximity Read ↗

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.